

Serial No 09/730,525, filed December 5, 2000  
Docket No. 20757USDIV6

### REMARKS


Claims 15-23 were previously pending. Claims 24-25 were canceled. New claims 34-44 are added herewith. With entry of these amendments, claims 15-23, and 26-44 are pending.

New claims 34-44 are supported throughout the specification as filed, for instance in Examples 38 and 43-45. No new matter has been added by these amendments.

New claims 34-44 correspond to claims of issued U.S. patent 6,512,162 ("the '162 patent"). New claim 34 corresponds substantially to claim 1 of the '162 patent; new claim 35 corresponds substantially to claim 2 of the '162 patent; new claim 36 corresponds substantially to claim 3 of the '162 patent; new claim 37 corresponds substantially to claim 4 of the '162 patent; new claim 38 corresponds substantially to claim 5 of the '162 patent; new claim 39 corresponds substantially to claim 6 of the '162 patent; new claim 40 corresponds substantially to claim 7 of the '162 patent; new claim 41 corresponds substantially to claim 8 of the '162 patent; new claim 42 corresponds substantially to claim 10 of the '162 patent; new claim 43 corresponds substantially to claim 11 of the '162 patent; and new claim 44 corresponds substantially to claim 13 of the '162 patent.

It is believed that no Extension of Time is required. However, if it is deemed that any other fees are necessary to maintain pendency of this application, then the Office is hereby authorized to charge Deposit Account No. 50-1744 (in the name of Syngenta) for payment of such fees.

Respectfully submitted,

  
Mary Kakefuda

Syngenta Biotechnology, Inc.  
P. O. Box 12257  
3054 Cornwallis Road  
Research Triangle Park, NC 27709-2257  
Telephone: 919-765-5071

Attorney for Applicants  
Registration No. 39,245

Date: November 7, 2003

BEST AVAILABLE COPY